CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform
Sponsor
Engineered NK cells are an exciting new therapeutic modality; however, technical challenges have hindered clinical success. Lentiviral vector transduction is a well-established step in producing CAR-T cell therapies, but traditional lentiviral vectors are not well suited to NK cells and yield poor transduction efficiency.
Baboon envelope glycoprotein pseudotyped lentiviral vector (BaEV-LV) has been shown to have robust transduction potential and, in a recent study, it performed better than vesicular-stomatitis-virus-G protein lentiviral vector (VSV-G-LV) in transducing primary NK cells.
Building on those results, this webinar presents new data on BaEV-LV transduction efficiency generated using the CliniMACS Prodigy® NK Cell Engineering platform. The NK cells were isolated first by depletion of CD3+ cells, followed by enrichment of CD56+ cells, then transduced with a BaEV encoding a CAR transgene, and expanded on the Prodigy system in a closed and automated process. These results strongly indicate that BaEV-LV provides superior transduction efficiency, and CAR-NK cell manufacturing with CliniMACS Prodigy generates highly pure CAR-NK cells with potent cytotoxic functionality.
Join the webinar to learn more about:
- The benefits of BaEV lentiviral vector transduction of NK cells
- How to implement the CliniMACS NK cell engineering process
- Utilizing the NK flow cytometry Express Modes on the MACSQuant Analyzer
- Leveraging Miltenyi Bioindustry expertise in analytical development
SPEAKERS
You might also like
Clinical-scale non-viral gene edited CAR-NK cells for cell therapy
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic
